Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis

Tiziana Life Sciences Ltd TLSA announced that the second patient (EA2) with non-active secondary progressive multiple sclerosis (SPMS) receiving intranasal foralumab had shown additional clinical improvements since their last reported improvement in September 2022.
The improvements were measured by the Expanded Disability Status Scale (EDSS), an FDA - recognized standard clinical outcome assessment measuring neural network functioning.
Related: Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient.
Before foralumab treatment, EA2's non-active SPMS disability had progressed, and EDSS worsened from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy that was discontinued in 2021.
In September 2022, 8 months after starting treatment with nasal foralumab, EA2 could walk 100 meters without a cane. EDSS score improved from 6.0 to 5.5. EA2's pyramidal score remained stable during this time. In December 2022, 11 months after starting treatment with intranasal foralumab, EA2 could walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to 5.0. EA2's pyramidal score continued to remain stable.
Price Action: TLSA shares are up 1.84% at $0.61 on the last check Tuesday.